Alabi Oladeji John, Adegboyega Fikayo Noah, Olawoyin Dolapo Samuel, Babatunde Oluwakemi Arinola
Department of Biochemistry, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Department of Biochemistry, Institute for Agriculture & Natural Sciences, College of Arts & Sciences, University of Nebraska-Lincoln, USA.
Heliyon. 2022 Jun 2;8(6):e09630. doi: 10.1016/j.heliyon.2022.e09630. eCollection 2022 Jun.
Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of hemoglobin (Hb) from glutamate to valine. This singular mutation results to disorderliness in red blood cells (RBCs) with advent of changes in RBC morphology and other pathological conditions. In the 1980s, intermittent red blood cell transfusions, opioids, and penicillin prophylaxis were the only available therapy for SCA and were commonly reserved for acute, life threatening complications. So far, the US Food and Drug Administration (FDA) has granted a total of four drugs approval for the prophylaxis and treatment of the clinical complications of SCD. Due to limitations (adherence, safety, adverse effects) of existing therapies in the prophylaxis and treatment of SCD complications in Nigerian children and their inaccessibility to approved drugs, the present study discusses the therapeutic effects of readily available functional food as one of the therapies or an adjunct therapy to tackle the sickle cell crisis in Nigerian Children.
镰状细胞病(SCD),也称为镰状细胞贫血(SCA),是一种结构性血红蛋白病,由单个核苷酸从GAG突变为GTG引起,这使得血红蛋白(Hb)β-珠蛋白链的氨基酸从谷氨酸变为缬氨酸。这种单一突变导致红细胞(RBC)出现紊乱,并伴随红细胞形态和其他病理状况的改变。在20世纪80年代,间歇性红细胞输血、阿片类药物和青霉素预防是SCA仅有的可用治疗方法,通常仅用于急性、危及生命的并发症。到目前为止,美国食品药品监督管理局(FDA)总共批准了四种药物用于预防和治疗SCD的临床并发症。由于现有疗法在预防和治疗尼日利亚儿童SCD并发症方面存在局限性(依从性、安全性、不良反应),且他们无法获得获批药物,本研究探讨了随手可得的功能性食品作为治疗方法之一或辅助治疗手段来应对尼日利亚儿童镰状细胞危机的治疗效果。